Concise reviews
Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis
Liwei Zhuanga,c, Junnan Lib,c, Yu Zhanga, Shibo Jia, Yue Lia, Yingying Zhaoa, Ben Lia, Wei Lia, Min Quana, Ying Duana, Hong Zhaoa, Danying Chenga, Xiaomei Wanga,c, Weini Oua,c, Huichun Xinga,c,
Corresponding author
hchxing@sohu.com
hchxing@ccmu.edu.com
Corresponding author at: Department of Hepatology Division 3, Beijing Ditan Hospital, Capital Medical University8 Jingshundong Street, Chaoyang District Beijing, 100015, China; Peking University Ditan Teaching Hospital, Beijing, China.
hchxing@ccmu.edu.com
Corresponding author at: Department of Hepatology Division 3, Beijing Ditan Hospital, Capital Medical University8 Jingshundong Street, Chaoyang District Beijing, 100015, China; Peking University Ditan Teaching Hospital, Beijing, China.
Read
2091
Timeswas read the article
402
Total PDF
1689
Total HTML
Share statistics
array:23 [ "pii" => "S1665268120301836" "issn" => "16652681" "doi" => "10.1016/j.aohep.2020.09.012" "estado" => "S300" "fechaPublicacion" => "2021-07-01" "aid" => "268" "copyrightAnyo" => "2020" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "rev" "cita" => "Ann Hepatol. 2021;23C:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S1665268120301812" "issn" => "16652681" "doi" => "10.1016/j.aohep.2020.09.010" "estado" => "S300" "fechaPublicacion" => "2021-07-01" "aid" => "266" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "rev" "cita" => "Ann Hepatol. 2021;23C:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Concise reviews</span>" "titulo" => "Visualising and quantifying intestinal permeability -where do we stand" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2870 "Ancho" => 2508 "Tamanyo" => 638982 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0050" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">(A): intestinal villi with intraepithelial gap (black arrow) and increased luminal fluorescence (white arrow) as a sign of increased permeability. (B): intestinal villi without gaps, intravascular fluorescence (black arrow), no increased intraluminal fluorescence.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Monica Rusticeanu, Vincent Zimmer, Frank Lammert" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Monica" "apellidos" => "Rusticeanu" ] 1 => array:2 [ "nombre" => "Vincent" "apellidos" => "Zimmer" ] 2 => array:2 [ "nombre" => "Frank" "apellidos" => "Lammert" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268120301812?idApp=UINPBA00004N" "url" => "/16652681/000000230000000C/v3_202212060650/S1665268120301812/v3_202212060650/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1665268120302246" "issn" => "16652681" "doi" => "10.1016/j.aohep.2020.100299" "estado" => "S300" "fechaPublicacion" => "2021-07-01" "aid" => "100299" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "dis" "cita" => "Ann Hepatol. 2021;23C:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:9 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Opinions</span>" "titulo" => "Progression of intraductal papillary neoplasm of the bile duct (IPNB): A proposed model through the observation of patients with non-resected tumors" "tienePdf" => "en" "tieneTextoCompleto" => "en" "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1806 "Ancho" => 3175 "Tamanyo" => 760356 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Proposed model of IPNB progression. The blue numbers indicate median survival of the patients treated by curative-intent resection of the IPNB, based on the author experience [<a class="elsevierStyleCrossRef" href="#bib0045">9</a>]. The red numbers indicate malignancy rate, and chance of lymph node involvement of curative-intent resection of the IPNB, based on the author experience, according to pathological examination [<a class="elsevierStyleCrossRef" href="#bib0045">9</a>]. †The indicated number may be imprecise due to small sample size, unpublished data. IPNB: intraductal papillary neoplasm of the bile duct, LN+: chance of lymph node involvement.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Vor Luvira" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Vor" "apellidos" => "Luvira" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268120302246?idApp=UINPBA00004N" "url" => "/16652681/000000230000000C/v3_202212060650/S1665268120302246/v3_202212060650/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Concise reviews</span>" "titulo" => "Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis" "tieneTextoCompleto" => true "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Yue Li, Yingying Zhao, Ben Li, Wei Li, Min Quan, Ying Duan, Hong Zhao, Danying Cheng, Xiaomei Wang, Weini Ou, Huichun Xing" "autores" => array:15 [ 0 => array:3 [ "nombre" => "Liwei" "apellidos" => "Zhuang" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 1 => array:3 [ "nombre" => "Junnan" "apellidos" => "Li" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 2 => array:3 [ "nombre" => "Yu" "apellidos" => "Zhang" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Shibo" "apellidos" => "Ji" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 4 => array:3 [ "nombre" => "Yue" "apellidos" => "Li" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "Yingying" "apellidos" => "Zhao" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "Ben" "apellidos" => "Li" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 7 => array:3 [ "nombre" => "Wei" "apellidos" => "Li" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 8 => array:3 [ "nombre" => "Min" "apellidos" => "Quan" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 9 => array:3 [ "nombre" => "Ying" "apellidos" => "Duan" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 10 => array:3 [ "nombre" => "Hong" "apellidos" => "Zhao" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 11 => array:3 [ "nombre" => "Danying" "apellidos" => "Cheng" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 12 => array:3 [ "nombre" => "Xiaomei" "apellidos" => "Wang" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 13 => array:3 [ "nombre" => "Weini" "apellidos" => "Ou" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 14 => array:4 [ "nombre" => "Huichun" "apellidos" => "Xing" "email" => array:2 [ 0 => "hchxing@sohu.com" 1 => "hchxing@ccmu.edu.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Science and Education, Beijing Ditan Hospital, Capital Medical University, Beijing, China" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Peking University Ditan Teaching Hospital, Beijing, China" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author at: Department of Hepatology Division 3, Beijing Ditan Hospital, Capital Medical University8 Jingshundong Street, Chaoyang District Beijing, 100015, China; Peking University Ditan Teaching Hospital, Beijing, China." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2516 "Ancho" => 2508 "Tamanyo" => 332905 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0065" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The flowchart of article selection.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">1</span><span class="elsevierStyleSectionTitle" id="sect0040">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">According to the reports of the World Health Organization (WHO), up to 71 million people were infected with the hepatitis C virus (HCV) around the world in 2015 [<a class="elsevierStyleCrossRef" href="#bib0005">1</a>]. The high rate of viral replication and mismatch in the process of replication leads to frequent viral mutations. The antiviral treatment regimen in the interferon era mainly included pegylated interferon, combined with ribavirin. However, this regimen had a low sustained virologic response (SVR) and was associated with more drug-related adverse events. With the clinical application of direct-acting antivirals (DAAs), the SVR rate significantly improved, and toxicity declined. However, previous studies have reported that the antiviral effectiveness of DAAs varies per genotype.</p><p id="par0010" class="elsevierStylePara elsevierViewall">The SVR rate of HCV genotype 3 (GT3) infection is relatively lower than that of other genotypes. In recent years, considerable progress has been made in the antiviral treatment of HCV-GT3 infection, using new drug regimens and drug combinations. The United States Food and Drug Administration (FDA) and the European Medicine Agency (EMA) approved the regimens, containing sofosbuvir (SOF)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>daclatasvir (DCV)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>ribavirin (RBV) in 2015 and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>velpatasvir (VEL)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV in 2016 for the treatment of HCV-GT3 infection. They also approved SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>voxilaprevir (VOX), as well as glecaprevir (GLE)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>pibrentasvir (PIB), in 2017 [<a class="elsevierStyleCrossRef" href="#bib0010">2</a>].</p><p id="par0015" class="elsevierStylePara elsevierViewall">In this meta-analysis, we systematically evaluated the pooled SVR rates of DAA regimens against HCV-GT3 infection in real-world studies.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2</span><span class="elsevierStyleSectionTitle" id="sect0045">Materials and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2.1</span><span class="elsevierStyleSectionTitle" id="sect0050">Literature search strategy</span><p id="par0020" class="elsevierStylePara elsevierViewall">The following terms were used to search PubMed, EMBASE, and Cochrane Library from January 1, 2016 to September 10, 2019: [“sofosbuvir” AND “daclatasvir” OR “Sovaldi”] OR [“sofosbuvir” AND “velpatasvir” OR “Epclusa”] OR [“sofosbuvir” AND “velpatasvir” AND “voxilaprevir” OR “Vosevi”] OR [“glecaprevir” AND “pibrentasvir” OR “Mavyret”].</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2.2</span><span class="elsevierStyleSectionTitle" id="sect0055">Inclusion and exclusion criteria</span><p id="par0025" class="elsevierStylePara elsevierViewall">Two researchers (ZLW and ZY) scanned the titles and abstracts of the papers independently and assessed eligible trials, according to the inclusion criteria. Articles, which were potentially suitable based on the inclusion criteria, were extracted for a full-text review. Any disagreements were resolved by discussion. The inclusion criteria for the articles were as follows: subject (assessment of patients with chronic HCV infection); intervention (SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX, or GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB); primary outcomes (SVR rate after 12/24 weeks); and study design (real-world studies). On the other hand, the exclusion criteria were as follows: 1) unavailability of valid data related to HCV-GT3 infection; 2) inclusion of less than 10 patients in the study during treatment or follow-up for effectiveness evaluation; and 3) summaries, case reports, or meta-analyses.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2.3</span><span class="elsevierStyleSectionTitle" id="sect0060">Data extraction</span><p id="par0030" class="elsevierStylePara elsevierViewall">Two authors (ZLW and ZY) read the full-text of articles independently. The information extracted from the articles included the demographics, main clinical characteristics of the patients, resistance-associated substitutions (RASs), average HCV RNA concentration at baseline, treatment regimen, drug dosage, therapy duration, SVR12/24, and virologic failure. Also, the authors resolved discrepancies by consultation with a third party (XHC).</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2.4</span><span class="elsevierStyleSectionTitle" id="sect0065">Data analysis</span><p id="par0035" class="elsevierStylePara elsevierViewall">Meta-analyses were conducted to determine the pooled SVR rate in all populations and subgroups, using the Freeman-Tukey double arcsine transformation in a random-effects model. Chi-square test was performed to compare the SVR rates of multiple groups. Also, Egger's test was conducted for evaluating potential publication bias. All analyses were performed in R 3.6.2 software with a meta package.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3</span><span class="elsevierStyleSectionTitle" id="sect0070">Results</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.1</span><span class="elsevierStyleSectionTitle" id="sect0075">Main characteristics of the studies and populations</span><p id="par0040" class="elsevierStylePara elsevierViewall">A total of 7328 HCV GT3-infected patients were examined in 34 studies, which were selected among 5525 screened articles (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). The studies were conducted in 22 countries: Germany (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>6), Brazil (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>4), USA (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3), France (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3), India (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3), Italy (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3), Pakistan (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3), Spain (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3), China (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2), Myanmar (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2), Norway (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2), Sweden (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2), Argentina(n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1), Austria(n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1), Denmark(n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1), UK(n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1), Finland(n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1), Ireland(n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1), Malaysia(n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1), Netherlands(n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1), Singapore(n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1), and Thailand (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1). In 34 studies, there were 37 treatment regimens, of which 73% were SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV (27/37, 73%), followed by SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV (5/37, 14%), SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX (3/37, 8%), and GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB (2/37, 5%), respectively. The total number of patients included is 7328, 4701 patients were treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV (4701/7328, 64%), followed by SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV (2266/7328, 31%), GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB (244/7328, 3%) and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX (117/7328, 2%), respectively.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0045" class="elsevierStylePara elsevierViewall">A summary of the demographic and clinical characteristics of the patients is presented in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. Patients with chronic HCV-GT3 infection, included in these real-world studies, also had diseases, such as hepatitis and decompensated cirrhosis. Some of these patients had refractory comorbidities, such as hepatocellular carcinoma (HCC), HIV/HBV co-infection, renal failure, history of liver transplantation, and history of DAA treatment failure.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.2</span><span class="elsevierStyleSectionTitle" id="sect0080">Pooled SVR rate for all patients</span><p id="par0050" class="elsevierStylePara elsevierViewall">A total of 7328 patients with HCV-GT3 infection were treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, and GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB. The pooled SVR12/24 rate was 92.07% (95% CI: 90.39–93.61%), as shown in <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>. The SVR12/24 rate was 84.97% (95% CI: 73.32–93.91%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX; 91.17% (95% CI: 89.23–92.94%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV; 95.08% (95% CI: 90.88–98.13%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV; and 98.54% (95% CI: 96.40–99.82%) in patients treated with GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0055" class="elsevierStylePara elsevierViewall">The results of Chi-square test indicated a significant difference in the SVR of four treatment regimens (P<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001). The two-by-two comparisons showed that GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB was superior to the other three regimens. The SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV regimen was superior to SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX, which could be related to the selection of populations with a history of DAA (SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL or LDV or DCV or OBV/PTV-r<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DSV) treatment failure in the SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX group. However, there was no significant difference between SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV or between SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.3</span><span class="elsevierStyleSectionTitle" id="sect0085">Stratification analysis (non-cirrhotic patients)</span><p id="par0060" class="elsevierStylePara elsevierViewall">According to the subgroup analysis of non-cirrhotic patients, the pooled SVR12/24 rate was 95.24% (95% CI: 93.50–96.75%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX, and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, as shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>A. The SVR12/24 rate was 95.36% (95% CI: 93.02–97.31%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV; and 94.61% (95% CI: 89.78–98.00%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV.</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.4</span><span class="elsevierStyleSectionTitle" id="sect0090">Stratification analysis (cirrhotic patients)</span><p id="par0065" class="elsevierStylePara elsevierViewall">The pooled SVR12/24 rate was 89.39% (95% CI: 86.07–92.33%) in cirrhotic patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX, and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, as shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>B. Based on the results, the SVR12/24 rate was 88.72% (95% CI: 85.19–91.86%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV; and 92.73% (95% CI: 81.85–99.03%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.5</span><span class="elsevierStyleSectionTitle" id="sect0095">Stratification analysis (treatment-naive patients)</span><p id="par0070" class="elsevierStylePara elsevierViewall">According to the subgroup analysis of treatment-naive patients, the pooled SVR12/24 rate in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV was 94.41% (95% CI: 92.02–96.42%), as shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>C. Also, the SVR rates in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV were 93.77% (95% CI: 90.15–96.65%) and 95.68% (95% CI: 90.73–98.87%), respectively.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.6</span><span class="elsevierStyleSectionTitle" id="sect0100">Stratification analysis (treatment-experienced patients)</span><p id="par0075" class="elsevierStylePara elsevierViewall">The pooled SVR12/24 rate of treatment-experienced patients with HCV-GT3 infection, treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, was 87.98% (95% CI: 84.31–91.25%), as shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>D. Also, the corresponding SVR12/24 rates were 87.90% (95% CI: 72.16–98.02%), 90.24% (95% CI: 78.42–97.89%), and 86.25% (95% CI: 82.85–89.36%), respectively.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.7</span><span class="elsevierStyleSectionTitle" id="sect0105">Sensitivity analysis of heterogeneity</span><p id="par0080" class="elsevierStylePara elsevierViewall">Changes in the results of sensitivity analysis ranged from 91.75% to 92.39% after excluding articles one by one, which is a very small range, indicating stable results.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.8</span><span class="elsevierStyleSectionTitle" id="sect0110">Publication bias</span><p id="par0085" class="elsevierStylePara elsevierViewall">The results of Egger’s test indicated no publication bias (<span class="elsevierStyleItalic">t</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.12404, DF<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>35, P<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.902), as shown in <a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a>.</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">4</span><span class="elsevierStyleSectionTitle" id="sect0115">Discussion</span><p id="par0090" class="elsevierStylePara elsevierViewall">In this review, the majority of treatment regimens in real-world studies included SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, which accounted for 73% of treatments. The SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV regimen was the first-line therapeutic regimen for all HCV genotypes, as recommended by the FDA and EMA. In our meta-analysis, the pooled SVR12/24 was 91.17% in HCV GT3-infected patients. The SVR rates of cirrhotic and non-cirrhotic patients were 88.72% and 95.36%, respectively. Also, the SVR rates of treatment-experienced and treatment-naive patients were 86.25% and 93.77%, respectively.</p><p id="par0095" class="elsevierStylePara elsevierViewall">The cirrhosis stage and history of treatment had significant effects on the antiviral effectiveness. In this regard, a phase III clinical study (ALLY-3) [<a class="elsevierStyleCrossRef" href="#bib0185">37</a>] showed that the pooled SVR12 rate of HCV GT3-infected patients, treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV, was 89%, of which there was 63% in patients with cirrhosis and 96% in patients without cirrhosis; therefore, the SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV regimen was not suitable for cirrhotic and treatment-experienced patients with HCV-GT3 infection. Also, Amit Goel et al. [<a class="elsevierStyleCrossRef" href="#bib0055">11</a>] evaluated patients with renal insufficiency (eGFR<30<span class="elsevierStyleHsp" style=""></span>ml/min), treated with SOF (200<span class="elsevierStyleHsp" style=""></span>mg per day), and reported an SVR12 rate of 86.36%. Moreover, Mucenic et al. [<a class="elsevierStyleCrossRef" href="#bib0110">22</a>] selected patients with virologic relapse following liver transplantation and reported an SVR12 rate of 84.62%. Also, Carlos Minguez [<a class="elsevierStyleCrossRef" href="#bib0115">23</a>], Jurgen K Rockstroh [<a class="elsevierStyleCrossRef" href="#bib0140">28</a>], and Karine Lacombe [<a class="elsevierStyleCrossRef" href="#bib0145">29</a>] in studies on HIV co-infected patients reported SVR rates of 90.57%, 92.31%, and 89.36%, respectively. Compared to renal insufficiency and virologic relapse following liver transplantation, the effect of HIV co-infection on the antiviral effectiveness of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV was relatively less significant.</p><p id="par0100" class="elsevierStylePara elsevierViewall">The SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV regimen, approved in 2017, is the first treatment regimen, which can be used for 12 weeks, regardless of HCV genotype and liver fibrosis stage. In the present study, the SVR rate of patients with HCV-GT3 infection was 95.08%, which is higher than that of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV. The SVR rates of cirrhotic, non-cirrhotic, treatment-naive, and treatment-experienced patients, treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, were 92.73%, 94.61%, 95.68%, and 90.24%, respectively. The effect of treatment history on the antiviral effectiveness of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV was more significant than that of cirrhosis stage.</p><p id="par0105" class="elsevierStylePara elsevierViewall">Belperio et al [<a class="elsevierStyleCrossRef" href="#bib0080">16</a>] gained the similar SVR rates of the GT3 HCV patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV compared with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV. In this meta-analysis the pooled SVR rate of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV was a little higher (95.08%) than that of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV (91.17%). This may be associated with the high SVR rate (100%, 21/21) from Tao’s study [<a class="elsevierStyleCrossRef" href="#bib0105">21</a>]. In non-cirrhotic patients, the SVR rates of the two regimens were almost the same (94.61% for SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV and 95.36% for SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV). However, in patients with cirrhosis, the SVR rate of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV was higher than that of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV (92.73% and 88.72%, respectively). Also, in cirrhotic patients, the SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV regimen was found to be more suitable than SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV.</p><p id="par0110" class="elsevierStylePara elsevierViewall">The GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB regimen was approved by the FDA and EMA, regardless of HCV genotypes. This regimen decreases the treatment duration to eight weeks for hepatitis and compensated cirrhotic patients. It can be also used for patients with renal dysfunction or even those undergoing dialysis. In a phase-III clinical study (ENDURANCE-3) [<a class="elsevierStyleCrossRef" href="#bib0190">38</a>] on patients treated with GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB for 8 or 12 weeks, the SVR rate was 95% in treatment-naive hepatitis patients with HCV-GT3 infection. Also, in the SURVEYOR-II Part-3 study [<a class="elsevierStyleCrossRef" href="#bib0195">39</a>], the SVR rate of HCV GT3-infected patients was 91% after 12 weeks of treatment; the patients were either treatment-naive or treatment-experienced, with or without cirrhosis. Moreover, in the EXPEDITION-2,4 studies [<a class="elsevierStyleCrossRef" href="#bib0200">40</a>,<a class="elsevierStyleCrossRef" href="#bib0205">41</a>], the SVR rate was 98% in patients after 8-12 weeks of treatment. In this real-world meta-analysis, the SVR rate of patients with HCV-GT3 infection, treated with GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB, could reach 97% or higher.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Our meta-analysis showed that the SVR rate of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX was 84.97%, which is lower than that of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, and GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB; this result may be related to previous resistance to DAA (SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL or LDV or DCV or OBV/PTV-r<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DSV) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX. The SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX regimen, which included a combination of three DAAs, was mainly designed as a treatment plan for patients with a history of DAA treatment failure. In this regard, the POLARIS-3 study [<a class="elsevierStyleCrossRef" href="#bib0210">42</a>] evaluated patients with liver cirrhosis, who were initially treated with DAAs. After eight weeks of treatment with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX, the SVR rate of patients with HCV-GT3 infection reached 96% (106/110).</p><p id="par0120" class="elsevierStylePara elsevierViewall">Moreover, in the POLARIS-1 study [<a class="elsevierStyleCrossRef" href="#bib0215">43</a>], the SVR rate of patients with HCV-GT3 infection was 95% (74/78) after 12 weeks of treatment. In this paper, some real-world studies [<a class="elsevierStyleCrossRef" href="#bib0040">8</a>,<a class="elsevierStyleCrossRef" href="#bib0060">12</a>,<a class="elsevierStyleCrossRef" href="#bib0085">17</a>] on patients with a history of DAA treatment failure reported SVR rates of 80.00%, 78.57%, and 93.33%, respectively. The antiviral effectiveness of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX in real-word studies was lower than that of registered clinical studies in patients with a history of DAA treatment failure. Also, in two real-word studies [<a class="elsevierStyleCrossRef" href="#bib0040">8</a>,<a class="elsevierStyleCrossRef" href="#bib0060">12</a>], the number of patients with virologic relapse was 6/30 and 3/42 during the follow-up, respectively.</p><p id="par0125" class="elsevierStylePara elsevierViewall">In real-world studies, the SVR rate of SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX was low in HCV GT3-infected patients with a history of DAA treatment failure, and the possibility of virologic relapse was still high. Overall, HCV-GT3 infection in patients with a history of DAA treatment failure poses challenges for the current antiviral treatments. In the present study, the pooled SVR rate of the four antiviral regimens for HCV-GT3 infection was 92.07%. The SVR rate of GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB was the highest (98.54%), and the treatment duration was the shortest (possibly eight weeks).</p><p id="par0130" class="elsevierStylePara elsevierViewall">Clinical trials [<a class="elsevierStyleCrossRef" href="#bib0185">37</a>,<a class="elsevierStyleCrossRef" href="#bib0220">44</a>] reported that patients with the presence of baseline RASs (Y93H and A30<span class="elsevierStyleHsp" style=""></span>K) in the NS5A gene had lower SVR rates, which was associated with decreased in vitro activity of DCV and VEL. In the ASTRAL-3 study [<a class="elsevierStyleCrossRef" href="#bib0225">45</a>], 84% SVR in the presence of Y93H compared to 97% in patients without Y93H was achieved from patients treated with SOF/VEL. However, in this meta-analysis only 6 articles completed RAVs test. It is interesting that all the 6 studies [<a class="elsevierStyleCrossRef" href="#bib0040">8</a>,<a class="elsevierStyleCrossRef" href="#bib0060">12</a>,<a class="elsevierStyleCrossRef" href="#bib0065">13</a>,<a class="elsevierStyleCrossRef" href="#bib0085">17</a>,<a class="elsevierStyleCrossRef" href="#bib0100">20</a>,<a class="elsevierStyleCrossRef" href="#bib0170">34</a>] draw a conclusion that RASs may be not associated with lower SVR rate. High SVR rates in patients completing therapy suggested that pretreatment RAS testing may not be necessary.</p><p id="par0135" class="elsevierStylePara elsevierViewall">This meta-analysis has limitations. We think that no strong conclusions can be drawn due to high heterogeneity in four DAA regimens administration in real-world setting from 22 countries, as well as small numbers of patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX and GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB. More studies are needed in the future in order to better analyze the antiviral effectiveness of DAAs in GT3 HCV patients in real-world studies.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">5</span><span class="elsevierStyleSectionTitle" id="sect0120">Conclusion</span><p id="par0140" class="elsevierStylePara elsevierViewall">According to our meta-analysis of real-world studies, the antiviral effectiveness of treatment regimens for HCV-GT3 infection, including SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV, GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB, and SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX, was good. The SVR rate of GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB was higher, and the treatment duration was shorter than other regimens. Based on the findings, SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX can be used as a treatment regimen following DAA treatment failure. Also, a history of DAA treatment failure still poses challenges for current treatments.</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Funding</span><p id="par0145" class="elsevierStylePara elsevierViewall">This study was supported by the <span class="elsevierStyleGrantSponsor" id="gs0005">National Science and Technology Major Project of China under Gran</span> [grant number <span class="elsevierStyleGrantNumber" refid="gs0005">2018ZX10302-206-003-006</span>]; the <span class="elsevierStyleGrantSponsor" id="gs0010">Capital’s Funds for Health Improvement and Research</span> [grant number <span class="elsevierStyleGrantNumber" refid="gs0010">CFH 2020-1-2171</span> and <span class="elsevierStyleGrantNumber" refid="gs0010">CFH 2018-2-2173</span>]; the <span class="elsevierStyleGrantSponsor" id="gs0015">Beijing Hospitals Authority Clinical Medicine Development of Special Funding</span> [grant number <span class="elsevierStyleGrantNumber" refid="gs0015">XMLX201837</span>]; the <span class="elsevierStyleGrantSponsor" id="gs0020">Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals</span> [grant number <span class="elsevierStyleGrantNumber" refid="gs0020">XXT26</span>].</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Conflict of interest</span><p id="par0150" class="elsevierStylePara elsevierViewall">All authors had approved the final version of the manuscript for publication and agreed to be accountable for all aspects of the work. The authors have read the journal's policy on conflicts of interest and they declare that they have no competing interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1814953" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1584599" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xpalclavsec1584598" "titulo" => "Abbreviations" ] 3 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 4 => array:3 [ "identificador" => "sec0010" "titulo" => "Materials and methods" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Literature search strategy" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Inclusion and exclusion criteria" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Data extraction" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Data analysis" ] ] ] 5 => array:3 [ "identificador" => "sec0035" "titulo" => "Results" "secciones" => array:8 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Main characteristics of the studies and populations" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Pooled SVR rate for all patients" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "Stratification analysis (non-cirrhotic patients)" ] 3 => array:2 [ "identificador" => "sec0055" "titulo" => "Stratification analysis (cirrhotic patients)" ] 4 => array:2 [ "identificador" => "sec0060" "titulo" => "Stratification analysis (treatment-naive patients)" ] 5 => array:2 [ "identificador" => "sec0065" "titulo" => "Stratification analysis (treatment-experienced patients)" ] 6 => array:2 [ "identificador" => "sec0070" "titulo" => "Sensitivity analysis of heterogeneity" ] 7 => array:2 [ "identificador" => "sec0075" "titulo" => "Publication bias" ] ] ] 6 => array:2 [ "identificador" => "sec0080" "titulo" => "Discussion" ] 7 => array:2 [ "identificador" => "sec0085" "titulo" => "Conclusion" ] 8 => array:2 [ "identificador" => "sec0090" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0095" "titulo" => "Conflict of interest" ] 10 => array:2 [ "identificador" => "xack640362" "titulo" => "Acknowledgement" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2020-07-21" "fechaAceptado" => "2020-09-21" "PalabrasClave" => array:1 [ "en" => array:2 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1584599" "palabras" => array:4 [ 0 => "Direct-acting antiviral" 1 => "Effectiveness" 2 => "Real-world" 3 => "Genotype 3 HCV" ] ] 1 => array:4 [ "clase" => "abr" "titulo" => "Abbreviations" "identificador" => "xpalclavsec1584598" "palabras" => array:14 [ 0 => "DAA" 1 => "DCV" 2 => "EMA" 3 => "FDA" 4 => "GLE" 5 => "HCV" 6 => "PIB" 7 => "RBV" 8 => "RASs" 9 => "SOF" 10 => "SVR" 11 => "VEL" 12 => "VOX" 13 => "WHO" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Patients with hepatitis C virus (HCV) genotype 3 (GT3) infection are resistant to direct-acting antiviral (DAA) treatments. This study aimed to analyze the effectiveness of sofosbuvir (SOF)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>daclatasvir (DCV) ± ribavirin (RBV); SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>velpatasvir (VEL)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV; SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>voxilaprevir (VOX); and glecaprevir (GLE)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>pibrentasvir (PIB) in the treatment of HCV GT3-infected patients in real-world studies.</p><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Articles were identified by searching the PubMed, EMBASE, and Cochrane Library databases from January 1, 2016 to September 10, 2019. The meta-analysis was conducted to determine the sustained virologic response (SVR) rate, using R 3.6.2 software.</p><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Thirty-four studies, conducted on a total of 7328 patients from 22 countries, met the inclusion criteria. The pooled SVR rate after 12/24 weeks of treatment was 92.07% (95% CI: 90.39–93.61%) for the evaluated regimens. Also, the SVR rate was 91.17% (95% CI: 89.23–92.94%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV; 95.08% (95% CI: 90.88–98.13%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV; 84.97% (95% CI: 73.32–93.91%) in patients treated with SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX; and 98.54% (95% CI: 96.40–99.82%) in patients treated with GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB. The pooled SVR rate of the four regimens was 95.24% (95% CI: 93.50–96.75%) in non-cirrhotic patients and 89.39% (95% CI: 86.07–92.33%) in cirrhotic patients. The pooled SVR rate was 94.41% (95% CI: 92.02–96.42%) in treatment-naive patients and 87.98% (95% CI: 84.31–91.25%) in treatment-experienced patients.</p><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">The SVR rate of GLE<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB was higher than other regimens. SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX can be used as a treatment regimen following DAA treatment failure.</p></span>" ] ] "multimedia" => array:5 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2516 "Ancho" => 2508 "Tamanyo" => 332905 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0065" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The flowchart of article selection.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 3754 "Ancho" => 2925 "Tamanyo" => 1014862 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0070" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">The forest plots of pooled SVR rates for all patients.</p>" ] ] 2 => array:8 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 2780 "Ancho" => 3175 "Tamanyo" => 967110 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0075" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">The forest plots of stratification analysis. (A) The forest plots of SVR rates in non-cirrhotic patients. (B) The forest plots of SVR rates in cirrhotic patients. (C) The forest plots of SVR rates in treatment-naive patients. (D) The forest plots of SVR rates in treatment-experienced patients.</p>" ] ] 3 => array:8 [ "identificador" => "fig0020" "etiqueta" => "Fig. 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1371 "Ancho" => 1508 "Tamanyo" => 58569 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0080" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">The funnel plot.</p>" ] ] 4 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0085" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">NA: Data not available for HCV GT3-infected patients; DSV: Dasabuvir; LDV: Ledipasvir; OBV/PTV-r: Ombitasvir/paritaprevir-ritonavir; VEL: Velpatasvir.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Year \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Country \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Main clinical characteristics of the patients \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resistance-associated substitutions \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mean age \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Sex (male/ female) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mean HCV RNA at baseline (log10 IU/mL) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No. of patients \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Regimen and dosage \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Treatment duration (weeks) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">SVR12/24 (n) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Virologic failure<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>(n) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sarwar et al. [<a class="elsevierStyleCrossRef" href="#bib0015">3</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pakistan \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">treatment experienced or with advanced fibrosis added RBV; with cirrhosis for 24 weeks; 58.4% with cirrhosis; 27.4% treatment experienced \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.34 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">113 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">102 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pariente et al. [<a class="elsevierStyleCrossRef" href="#bib0020">4</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">France \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59.0% with cirrhosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">117 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">103 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mangia et al. [<a class="elsevierStyleCrossRef" href="#bib0025">5</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Italy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">all with cirrhosis and portal hypertension, 54.1% transient elastography results >20<span class="elsevierStyleHsp" style=""></span>K<span class="elsevierStyleHsp" style=""></span>Pa; 72.8% treatment naïve; 5.3% with HCC; 9.8% HIV positive; 14.6% past intravenous drug use; 18.5% alcohol abuse; 17.6% with diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">52.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">175/30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.53<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>4.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">205 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL (100<span class="elsevierStyleHsp" style=""></span>mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 relapses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Macken et al. [<a class="elsevierStyleCrossRef" href="#bib0030">6</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">England \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">91% with cirrhosis, 63.3% treatment naive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">256 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)±RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">216 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lobato et al. [<a class="elsevierStyleCrossRef" href="#bib0035">7</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Brazil \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">817 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">736 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Llaneras et al. [<a class="elsevierStyleCrossRef" href="#bib0040">8</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Spain \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">all received a DAA-based interferon-free regimen: SOF and DCV or VEL or LDV; 43.3% with cirrhosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">of 6 relapses 1 detected with L28S, M31<span class="elsevierStyleHsp" style=""></span>L and D168<span class="elsevierStyleHsp" style=""></span>G, 1 with Y93H, 2 not detected, 2 NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL (100<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX (100<span class="elsevierStyleHsp" style=""></span>mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 relapses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Hlaing et al. [<a class="elsevierStyleCrossRef" href="#bib0045">9</a>]</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="middle">2019</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">Myanmar</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.16% treatment experienced; 67.6% with cirrhosis or advanced fibrosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">NA</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">NA</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">NA</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">193 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">187 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 relapses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">83 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL (100<span class="elsevierStyleHsp" style=""></span>mg)±RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">75 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 relapses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Han et al. [<a class="elsevierStyleCrossRef" href="#bib0050">10</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">China \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">62.5% with history of drug abuse; 25% with compensated cirrhosis; 9.4% renal impairment; 96.9% treatment naive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">44.26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26/6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.91 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)±RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 relapse \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Goel et al. [<a class="elsevierStyleCrossRef" href="#bib0055">11</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">India \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">all eGFR<30<span class="elsevierStyleHsp" style=""></span>ml/min, 18.2% with cirrhosis; \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (200<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Degasperi et al. [<a class="elsevierStyleCrossRef" href="#bib0060">12</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Italy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">all with a prior DAA failure: SOF and VEL or LDV, or OBV/PTV-r<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DSV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">of 3 relapses 1 detected with Y93H, 2 NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL (100<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX (100<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 relapses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">D'Ambrosio et al. [<a class="elsevierStyleCrossRef" href="#bib0065">13</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Italy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">of 2 relapses 1 detected with Y93H and L31I \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">68 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GLE (300<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB (120<span class="elsevierStyleHsp" style=""></span>mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8-16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">66 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 relapses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Butt et al. [<a class="elsevierStyleCrossRef" href="#bib0070">14</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pakistan \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">84.2% treatment naïve, 52.5% with cirrhosis, \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">47.06 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33/68 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">101 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">96 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Berg et al. [<a class="elsevierStyleCrossRef" href="#bib0075">15</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Germany \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 weeks for treatment-naïve and non-cirrhotic patients, 12 weeks for treatment-naïve and cirrhotic patients, 16 weeks for treatment-experienced patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">176 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GLE (300<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PIB (120<span class="elsevierStyleHsp" style=""></span>mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8-16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">174 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Belperio et al. [<a class="elsevierStyleCrossRef" href="#bib0080">16</a>]</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="middle">2019</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">USA</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42.1% with cirrhosis, 3.03% with HCC, 22.9% treatment experienced \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">58.95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">868/23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.05 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">891 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">796 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26.5% with cirrhosis, 2.42% with HCC, 9.7% treatment experienced \t\t\t\t\t\t\n \t\t\t\t</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">58.95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1662/73 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.05 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1735 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL (100<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1573 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Belperio et al. [<a class="elsevierStyleCrossRef" href="#bib0085">17</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">USA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">all treatment experienced: SOF and DCV or VEL or LDV, 51.1% with cirrhosis, 4.44% with HCC, 2.22% with HIV coinfected, 37.8% with diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51/0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">45 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL (100<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VOX (100<span class="elsevierStyleHsp" style=""></span>mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Araujo et al. [<a class="elsevierStyleCrossRef" href="#bib0090">18</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Brazil \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.5% with cirrhosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 virologic failure \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Wehmeyer et al. [<a class="elsevierStyleCrossRef" href="#bib0095">19</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2018 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Germany \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28.75% treatment experienced, 33.75% with cirrhosis, 15% with HIV coinfected \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">80 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">76 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Felden et al. [<a class="elsevierStyleCrossRef" href="#bib0100">20</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2018 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Germany \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24.8% treatment experienced, 26.6% with cirrhosis, 8.56% with HIV coinfected \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 patients with baseline NS5A RASs (Y93H, A30<span class="elsevierStyleHsp" style=""></span>K or L31<span class="elsevierStyleHsp" style=""></span>M) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">222 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL (100<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">213 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Tao et al. [<a class="elsevierStyleCrossRef" href="#bib0105">21</a>]</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="middle">2018</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">China</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34.6% with cirrhosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">41.71 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">48/33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">81 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">71 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 relapses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">23.8% with cirrhosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">37.38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13/8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.04 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>VEL (100<span class="elsevierStyleHsp" style=""></span>mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mucenic et al. [<a class="elsevierStyleCrossRef" href="#bib0110">22</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2018 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Brazil \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">all liver transplant recipients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 relapses and 2 non-responses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Minguez et al. [<a class="elsevierStyleCrossRef" href="#bib0115">23</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2018 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Spain \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">all HIV-coinfected \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">48 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mehta et al. [<a class="elsevierStyleCrossRef" href="#bib0120">24</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2018 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">India \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">372 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">362 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 non-responses, 2 breakthroughs, and 10 relapses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Marciano et al. [<a class="elsevierStyleCrossRef" href="#bib0125">25</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2018 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Argentina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">89.4% with cirrhosis, \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lim et al. [<a class="elsevierStyleCrossRef" href="#bib0130">26</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2018 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">India, Myanmar, Pakistan, Thailand, Singapore, and Malaysia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">310 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">282 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Kwo et al. [<a class="elsevierStyleCrossRef" href="#bib0135">27</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2018 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">USA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">64% liver transplant, 36% with decompensated cirrhosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 breakthrough \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rockstroh et al. [<a class="elsevierStyleCrossRef" href="#bib0140">28</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Germany \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">all HIV-coinfected and with an advanced stage of cirrhosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lacombe et al. [<a class="elsevierStyleCrossRef" href="#bib0145">29</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">France \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">all HIV-coinfected and with advanced liver disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 relapses and 1 undefined virologic failure \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hezode et al. [<a class="elsevierStyleCrossRef" href="#bib0150">30</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">France \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">76.9% with cirrhosis, 8.1% with HCC, 9.0% post-liver transplant HCV recurrence, 9.0% pre-liver/renal transplant, 71.2% treatment experienced, 14.1% HIV-coinfected, 2.1% HBV-coinfected \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">245/88 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">333 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">278 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 breakthroughs, 32 relapses, and 9 undefined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dalgard et al. [<a class="elsevierStyleCrossRef" href="#bib0155">31</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Denmark, Sweden, Norway, and Finland \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51.8% treatment experienced, 73.2% with cirrhosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">135/60 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">193 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">177 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cornberg et al. [<a class="elsevierStyleCrossRef" href="#bib0160">32</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Germany \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32.7% with cirrhosis, 29.1% treatment experienced \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">220 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)±RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">207 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gray et al. [<a class="elsevierStyleCrossRef" href="#bib0165">33</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ireland \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28.9% treatment experienced \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">76 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">67 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sette-Jr et al. [<a class="elsevierStyleCrossRef" href="#bib0170">34</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Brazil \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">35.7% with cirrhosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">of 4 relapses 2 detected with Y93H, 2 not done \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 relapses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Alonso et al. [<a class="elsevierStyleCrossRef" href="#bib0175">35</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Spain \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26% with decompensated cirrhosis, 45% treatment experienced \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">110/21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">131 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12-24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">123 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 relapses, 1 breakthrough \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Welzel et al. [<a class="elsevierStyleCrossRef" href="#bib0180">36</a>] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2016 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Germany, Austria, Netherlands, Sweden, and Norway \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">84.9% with cirrhosis, 60.2% treatment experienced \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">93 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SOF (400<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV (60<span class="elsevierStyleHsp" style=""></span>mg)<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>RBV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">82 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Relapse or breakthrough or undefined virologic failure.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">The main characteristics of studies included in the meta-analysis.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:45 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "[1]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis C fact sheet" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "World Health Organization" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2018" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "[2]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A. 2019 Update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E.J. Smolders" 1 => "A.M.E. Jansen" 2 => "P.G.J. Ter Horst" 3 => "J. Rockstroh" 4 => "D.J. Back" 5 => "D.M. Burger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40262-019-00774-0" "Revista" => array:6 [ "tituloSerie" => "Clin Pharmacokinet" "fecha" => "2019" "volumen" => "58" "paginaInicial" => "1237" "paginaFinal" => "1263" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31114957" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "[3]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Sarwar" 1 => "S. Tarique" 2 => "A. Aleem" 3 => "A.A. Khan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MEG.0000000000001376" "Revista" => array:6 [ "tituloSerie" => "Eur J Gastroenterol Hepatol" "fecha" => "2019" "volumen" => "31" "paginaInicial" => "1035" "paginaFinal" => "1039" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31274596" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "[4]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Pariente" 1 => "J.P. Arpurt" 2 => "A.J. Remy" 3 => "I. Rosa-Hezode" 4 => "X. Causse" 5 => "F. Heluwaert" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.lpm.2018.06.019" "Revista" => array:6 [ "tituloSerie" => "Presse Med" "fecha" => "2019" "volumen" => "48" "paginaInicial" => "e101" "paginaFinal" => "e110" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30853287" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "[5]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SVR12 higher than 97% in GT3 cirrhotic patients with evidence of portal hypertension treated with SOF/VEL without ribavirin: A nation-wide cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Mangia" 1 => "G. Cenderello" 2 => "M. Copetti" 3 => "G. Verucchi" 4 => "V. Piazzolla" 5 => "C. Lorusso" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Cells" "fecha" => "2019" "paginaInicial" => "8" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "[6]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Macken" 1 => "W. Gelson" 2 => "M. Priest" 3 => "G. Abouda" 4 => "S. Barclay" 5 => "A. Fraser" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jmv.25552" "Revista" => array:6 [ "tituloSerie" => "J Med Virol" "fecha" => "2019" "volumen" => "91" "paginaInicial" => "1979" "paginaFinal" => "1988" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31329295" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "[7]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.M.O. Lobato" 1 => "L. Codes" 2 => "G.F. Silva" 3 => "A.F.M. Souza" 4 => "H.S.M. Coelho" 5 => "M.L.A. Pedroso" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.aohep.2019.08.001" "Revista" => array:6 [ "tituloSerie" => "Ann Hepatol" "fecha" => "2019" "volumen" => "18" "paginaInicial" => "849" "paginaFinal" => "854" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31537509" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "[8]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Llaneras" 1 => "M. Riveiro-Barciela" 2 => "S. Lens" 3 => "M. Diago" 4 => "A. Cachero" 5 => "J. Garcia-Samaniego" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2019.06.002" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2019" "volumen" => "71" "paginaInicial" => "666" "paginaFinal" => "672" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31203153" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "[9]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N.K.T. Hlaing" 1 => "G. Nangia" 2 => "K.T. Tun" 3 => "S. Lin" 4 => "M.Z. Maung" 5 => "K.T. Myint" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jvh.13133" "Revista" => array:6 [ "tituloSerie" => "J Viral Hepat" "fecha" => "2019" "volumen" => "26" "paginaInicial" => "1186" "paginaFinal" => "1199" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31104344" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "[10]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Q. Han" 1 => "X. Fan" 2 => "X. Wang" 3 => "Y. Wang" 4 => "H. Deng" 5 => "X. Zhang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12985-019-1184-y" "Revista" => array:5 [ "tituloSerie" => "Virol J" "fecha" => "2019" "volumen" => "16" "paginaInicial" => "74" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31159813" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "[11]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Goel" 1 => "D.S. Bhadauria" 2 => "A. Kaul" 3 => "P. Verma" 4 => "M. Mehrotra" 5 => "A. Gupta" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/nep.13222" "Revista" => array:6 [ "tituloSerie" => "Nephrology (Carlton)" "fecha" => "2019" "volumen" => "24" "paginaInicial" => "316" "paginaFinal" => "321" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29327401" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "[12]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Degasperi" 1 => "A. Spinetti" 2 => "A. Lombardi" 3 => "S. Landonio" 4 => "M.C. Rossi" 5 => "L. Pasulo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2019.07.020" "Revista" => array:6 [ "tituloSerie" => "Journal of hepatology" "fecha" => "2019" "volumen" => "71" "paginaInicial" => "1106" "paginaFinal" => "1115" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31433303" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "[13]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. D’Ambrosio" 1 => "L. Pasulo" 2 => "M. Puoti" 3 => "M. Vinci" 4 => "M. Schiavini" 5 => "S. Lazzaroni" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2018.11.011" "Revista" => array:6 [ "tituloSerie" => "Journal of Hepatology" "fecha" => "2019" "volumen" => "70" "paginaInicial" => "379" "paginaFinal" => "387" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30472321" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "[14]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Z. Butt" 1 => "S.M.A. Shah" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.12669/pjms.35.2.637" "Revista" => array:6 [ "tituloSerie" => "Pak J Med Sci" "fecha" => "2019" "volumen" => "35" "paginaInicial" => "409" "paginaFinal" => "413" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31086524" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "[15]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Berg" 1 => "U. Naumann" 2 => "A. Stoehr" 3 => "C. Sick" 4 => "C. John" 5 => "G. Teuber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/apt.15222" "Revista" => array:6 [ "tituloSerie" => "Alimentary Pharmacology and Therapeutics" "fecha" => "2019" "volumen" => "49" "paginaInicial" => "1052" "paginaFinal" => "1059" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30874328" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "[16]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "P.S. Belperio" 1 => "T.A. Shahoumian" 2 => "T.P. Loomis" 3 => "L.A. Mole" 4 => "L.I. Backus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2018.09.018" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2019" "volumen" => "70" "paginaInicial" => "15" "paginaFinal" => "23" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30266283" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "[17]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P.S. Belperio" 1 => "T.A. Shahoumian" 2 => "T.P. Loomis" 3 => "L.I. Backus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jvh.13115" "Revista" => array:6 [ "tituloSerie" => "Journal of Viral Hepatitis" "fecha" => "2019" "volumen" => "26" "paginaInicial" => "980" "paginaFinal" => "990" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31012179" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "[18]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Araujo" 1 => "V. Valenzuela-Granados" 2 => "A.B. Lopes" 3 => "M.T. Michalczuk" 4 => "A. Mantovani" 5 => "M.R. Alvares-da-Silva" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.aohep.2018.09.004" "Revista" => array:6 [ "tituloSerie" => "Ann Hepatol" "fecha" => "2019" "volumen" => "18" "paginaInicial" => "450" "paginaFinal" => "455" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31028014" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "[19]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.H. Wehmeyer" 1 => "P. Ingiliz" 2 => "S. Christensen" 3 => "D. Hueppe" 4 => "T. Lutz" 5 => "K.G. Simon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jmv.24903" "Revista" => array:6 [ "tituloSerie" => "J Med Virol" "fecha" => "2018" "volumen" => "90" "paginaInicial" => "304" "paginaFinal" => "312" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28710853" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "[20]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. von Felden" 1 => "J. Vermehren" 2 => "P. Ingiliz" 3 => "S. Mauss" 4 => "T. Lutz" 5 => "K.G. Simon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/apt.14592" "Revista" => array:6 [ "tituloSerie" => "Alimentary Pharmacology and Therapeutics" "fecha" => "2018" "volumen" => "47" "paginaInicial" => "1288" "paginaFinal" => "1295" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29536554" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "[21]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y.C. Tao" 1 => "R. Deng" 2 => "M.L. Wang" 3 => "D.D. Lv" 4 => "M. Yuan" 5 => "Y.H. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12985-018-1066-8" "Revista" => array:5 [ "tituloSerie" => "Virol J" "fecha" => "2018" "volumen" => "15" "paginaInicial" => "150" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30285800" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "[22]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Mucenic" 1 => "A. Bandeira de Mello Brandao" 2 => "C.A. Marroni" 3 => "A. Medeiros Fleck Jr." 4 => "M.L. Zanotelli" 5 => "G. Kiss" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.transproceed.2018.02.001" "Revista" => array:6 [ "tituloSerie" => "Transplant Proc" "fecha" => "2018" "volumen" => "50" "paginaInicial" => "769" "paginaFinal" => "771" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29661434" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "[23]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Mínguez" 1 => "M. García-Deltoro" 2 => "J. Flores" 3 => "M.J. Galindo" 4 => "M. Montero" 5 => "S. Reus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0000000000001699" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2018" "volumen" => "32" "paginaInicial" => "337" "paginaFinal" => "346" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29309345" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "[24]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Mehta" 1 => "R. Mahajan" 2 => "V. Midha" 3 => "V. Narang" 4 => "K. Kaur" 5 => "A. Singh" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jceh.2017.06.003" "Revista" => array:6 [ "tituloSerie" => "J Clin Exp Hepatol" "fecha" => "2018" "volumen" => "8" "paginaInicial" => "7" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29743791" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "[25]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Marciano" 1 => "L. Haddad" 2 => "M.V. Reggiardo" 3 => "M. Peralta" 4 => "C. Vistarini" 5 => "M. Marino" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jmv.25033" "Revista" => array:6 [ "tituloSerie" => "J Med Virol" "fecha" => "2018" "volumen" => "90" "paginaInicial" => "951" "paginaFinal" => "958" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29350402" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "[26]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Findings from a large Asian chronic hepatitis C real-life study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.G. Lim" 1 => "W.W. Phyo" 2 => "S.R. Shah" 3 => "K.M. Win" 4 => "S. Hamid" 5 => "T. Piratvisuth" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jvh.12989" "Revista" => array:6 [ "tituloSerie" => "Journal of Viral Hepatitis" "fecha" => "2018" "volumen" => "25" "paginaInicial" => "1533" "paginaFinal" => "1542" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30141214" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "[27]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Kwo" 1 => "M.W. Fried" 2 => "K.R. Reddy" 3 => "C. Soldevila-Pico" 4 => "S. Khemichian" 5 => "J. Darling" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep4.1156" "Revista" => array:6 [ "tituloSerie" => "Hepatol Commun" "fecha" => "2018" "volumen" => "2" "paginaInicial" => "354" "paginaFinal" => "363" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29619415" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "[28]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.K. Rockstroh" 1 => "P. Ingiliz" 2 => "J. Petersen" 3 => "M. Peck-Radosavljevic" 4 => "T.M. Welzel" 5 => "M. Van der Valk" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3851/IMP3108" "Revista" => array:6 [ "tituloSerie" => "Antivir Ther" "fecha" => "2017" "volumen" => "22" "paginaInicial" => "225" "paginaFinal" => "236" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27845298" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "[29]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Lacombe" 1 => "H. Fontaine" 2 => "C. Dhiver" 3 => "S. Metivier" 4 => "E. Rosenthal" 5 => "T. Antonini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAI.0000000000001342" "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2017" "volumen" => "75" "paginaInicial" => "97" "paginaFinal" => "107" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28272163" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "[30]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Hezode" 1 => "P. Lebray" 2 => "V. De Ledinghen" 3 => "F. Zoulim" 4 => "V. Di Martino" 5 => "N. Boyer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/liv.13383" "Revista" => array:7 [ "tituloSerie" => "Liver Int" "fecha" => "2017" "volumen" => "37" "paginaInicial" => "1314" "paginaFinal" => "1324" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28177199" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1063458499903060" "estado" => "S300" "issn" => "10634584" ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "[31]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Dalgard" 1 => "O. Weiland" 2 => "G. Noraberg" 3 => "L. Karlsen" 4 => "L. Heggelund" 5 => "M. Farkkila" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "PLoS One" "fecha" => "2017" "volumen" => "12" ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "[32]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Cornberg" 1 => "J. Petersen" 2 => "A. Schober" 3 => "S. Mauss" 4 => "K.H. Boker" 5 => "R. Link" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2017" "volumen" => "45" "paginaInicial" => "688" "paginaFinal" => "700" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "[33]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Gray" 1 => "A. O’Leary" 2 => "C. Bergin" 3 => "M. Cannon" 4 => "G. Courtney" 5 => "O. Crosbie" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/17474124.2017.1292850" "Revista" => array:6 [ "tituloSerie" => "Expert Review of Gastroenterology and Hepatology" "fecha" => "2017" "volumen" => "11" "paginaInicial" => "593" "paginaFinal" => "601" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28276815" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "[34]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Cheinquer" 1 => "H. Sette Jr." 2 => "F.H. Wolff" 3 => "A. de Araujo" 4 => "S. Coelho-Borges" 5 => "S.R.P. Soares" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5604/01.3001.0010.2717" "Revista" => array:6 [ "tituloSerie" => "Ann Hepatol" "fecha" => "2017" "volumen" => "16" "paginaInicial" => "727" "paginaFinal" => "733" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28809742" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "[35]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Alonso" 1 => "M. Riveiro-Barciela" 2 => "I. Fernandez" 3 => "D. Rincon" 4 => "Y. Real" 5 => "S. Llerena" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jvh.12648" "Revista" => array:6 [ "tituloSerie" => "J Viral Hepat" "fecha" => "2017" "volumen" => "24" "paginaInicial" => "304" "paginaFinal" => "311" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27935168" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "[36]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.M. Welzel" 1 => "J. Petersen" 2 => "K. Herzer" 3 => "P. Ferenci" 4 => "M. Gschwantler" 5 => "H. Wedemeyer" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Gut" "fecha" => "2016" "volumen" => "65" "paginaInicial" => "1861" "paginaFinal" => "1870" ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "[37]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.R. Nelson" 1 => "J.N. Cooper" 2 => "J.P. Lalezari" 3 => "E. Lawitz" 4 => "P.J. Pockros" 5 => "N. Gitlin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.27726" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2015" "volumen" => "61" "paginaInicial" => "1127" "paginaFinal" => "1135" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25614962" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "[38]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Zeuzem" 1 => "G.R. Foster" 2 => "S. Wang" 3 => "A. Asatryan" 4 => "E. Gane" 5 => "J.J. Feld" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1702417" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2018" "volumen" => "378" "paginaInicial" => "354" "paginaFinal" => "369" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29365309" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "[39]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Wyles" 1 => "F. Poordad" 2 => "S. Wang" 3 => "L. Alric" 4 => "F. Felizarta" 5 => "P.Y. Kwo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.29541" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2018" "volumen" => "67" "paginaInicial" => "514" "paginaFinal" => "523" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28926120" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "[40]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Gane" 1 => "E. Lawitz" 2 => "D. Pugatch" 3 => "G. Papatheodoridis" 4 => "N. Brau" 5 => "A. Brown" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1704053" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2017" "volumen" => "377" "paginaInicial" => "1448" "paginaFinal" => "1455" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29020583" "web" => "Medline" ] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "[41]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.K. Rockstroh" 1 => "K. Lacombe" 2 => "R.M. Viani" 3 => "C. Orkin" 4 => "D. Wyles" 5 => "A.F. Luetkemeyer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/cid/ciy220" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2018" "volumen" => "67" "paginaInicial" => "1010" "paginaFinal" => "1017" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29566246" "web" => "Medline" ] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "[42]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I.M. Jacobson" 1 => "E. Lawitz" 2 => "E.J. Gane" 3 => "B.E. Willems" 4 => "P.J. Ruane" 5 => "R.G. Nahass" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2017.03.047" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2017" "volumen" => "153" "paginaInicial" => "113" "paginaFinal" => "122" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28390869" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "[43]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Bourliere" 1 => "S.C. Gordon" 2 => "S.L. Flamm" 3 => "C.L. Cooper" 4 => "A. Ramji" 5 => "M. Tong" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1613512" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2017" "volumen" => "376" "paginaInicial" => "2134" "paginaFinal" => "2146" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28564569" "web" => "Medline" ] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "[44]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D. Hernandez" 1 => "N. Zhou" 2 => "J. Ueland" 3 => "A. Monikowski" 4 => "F. McPhee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcv.2012.12.020" "Revista" => array:6 [ "tituloSerie" => "J Clin Virol." "fecha" => "2013" "volumen" => "57" "paginaInicial" => "13" "paginaFinal" => "18" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23384816" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "[45]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sofosbuvir and velpatasvir for HCV genotpye 2 and 3 infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.R. Foster" 1 => "N. Afdhal" 2 => "S.K. Roberts" 3 => "N. Brau" 4 => "E.J. Gane" 5 => "S. Pianko" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1512612" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med." "fecha" => "2015" "volumen" => "373" "paginaInicial" => "2608" "paginaFinal" => "2617" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26575258" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack640362" "titulo" => "Acknowledgement" "texto" => "<p id="par0155" class="elsevierStylePara elsevierViewall">Author Contributions: Study concept and design: Liwei Zhuang, and Huichun Xing; initial article screen: Shibo Ji, Yue Li, Ben Li, Ying Duan, Danying Cheng, Yu Zhang, Min Quan, Hong Zhao and Wei Li; finial article screen: Liwei Zhuang, and Yu Zhang; analysis and interpretation of data: Liwei Zhuang, Junnan Li, Yu Zhang, and Huichun Xing; drafting of the manuscript: Liwei Zhuang; critical revision of the manuscript for important intellectual content: Xiaomei Wang, Weini Ou, and Huichun Xing; statistical analysis: Liwei Zhuang, Junnan Li and Huichun Xing.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/000000230000000C/v3_202212060650/S1665268120301836/v3_202212060650/en/main.assets" "Apartado" => array:4 [ "identificador" => "77774" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Concise reviews" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/000000230000000C/v3_202212060650/S1665268120301836/v3_202212060650/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268120301836?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 5 | 0 | 5 |
| 2024 October | 44 | 2 | 46 |
| 2024 September | 50 | 3 | 53 |
| 2024 August | 49 | 9 | 58 |
| 2024 July | 35 | 7 | 42 |
| 2024 June | 54 | 5 | 59 |
| 2024 May | 48 | 7 | 55 |
| 2024 April | 72 | 7 | 79 |
| 2024 March | 76 | 12 | 88 |
| 2024 February | 52 | 10 | 62 |
| 2024 January | 52 | 9 | 61 |
| 2023 December | 43 | 5 | 48 |
| 2023 November | 37 | 10 | 47 |
| 2023 October | 73 | 15 | 88 |
| 2023 September | 50 | 2 | 52 |
| 2023 August | 52 | 3 | 55 |
| 2023 July | 27 | 9 | 36 |
| 2023 June | 35 | 7 | 42 |
| 2023 May | 63 | 8 | 71 |
| 2023 April | 47 | 0 | 47 |
| 2023 March | 36 | 4 | 40 |
| 2023 February | 28 | 2 | 30 |
| 2023 January | 20 | 4 | 24 |
| 2022 December | 45 | 7 | 52 |
| 2022 November | 28 | 10 | 38 |
| 2022 October | 20 | 8 | 28 |
| 2022 September | 18 | 16 | 34 |
| 2022 August | 20 | 13 | 33 |
| 2022 July | 17 | 14 | 31 |
| 2022 June | 19 | 9 | 28 |
| 2022 May | 19 | 6 | 25 |
| 2022 April | 22 | 18 | 40 |
| 2022 March | 40 | 10 | 50 |
| 2022 February | 31 | 6 | 37 |
| 2022 January | 42 | 7 | 49 |
| 2021 December | 18 | 17 | 35 |
| 2021 November | 32 | 6 | 38 |
| 2021 October | 50 | 22 | 72 |
| 2021 September | 43 | 12 | 55 |
| 2021 August | 49 | 8 | 57 |
| 2021 July | 82 | 14 | 96 |
| 2021 June | 7 | 5 | 12 |
| 2021 May | 4 | 3 | 7 |
| 2021 April | 17 | 11 | 28 |
| 2021 March | 3 | 4 | 7 |
| 2021 February | 3 | 7 | 10 |
| 2021 January | 5 | 10 | 15 |
| 2020 December | 5 | 10 | 15 |
| 2020 November | 2 | 9 | 11 |
Show all
